Liliya Sivcheva

Statistics

Publications

Citations

1.7K

H-Index

Active since

2016

Affiliations

National Institute of Emergency Medicine "Pirogov"(Current)

University Hospital Cologne

Roche (United Kingdom)

Rigshospitalet

AbbVie (United States)

Liliya Sivcheva is an author at National Institute of Emergency Medicine "Pirogov" specializing in immunotherapy, chronic lymphocytic leukemia therapy, and medicine.

Publications per year

2016–2024

Publications

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

Kirsten Fischer, Othman Al‐Sawaf, Jasmin Bahlo et al. · New England Journal of Medicine · 2019 · 852 citations

Pharmacy, Pharmacology, Pharmacotherapy +14

Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo‐controlled trials

James B. Bussel, Donald M. Arnold, Elliot Grossbard et al. · American Journal of Hematology · 2018 · 351 citations · Full text

Medicine, Hematology, Pharmacology +11

Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial

Othman Al‐Sawaf, Can Zhang, Maneesh Tandon et al. · The Lancet Oncology · 2020 · 327 citations

Medicine, Hematology, Immunology +15

Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study

Othman Al‐Sawaf, Sandra Robrecht, Can Zhang et al. · Blood · 2024 · 127 citations · Full text

Medicine, Hematology, Oncology +12

Final Results from PROUD-PV a Randomized Controlled Phase 3 Trial Comparing Ropeginterferon Alfa-2b to Hydroxyurea in Polycythemia Vera Patients

Heinz Gisslinger, Christoph Klade, Pencho Georgiev et al. · Blood · 2016 · 28 citations

Pharmacy, Pharmacology, Pharmacotherapy +3

1–5 of 7